MannKind (MNKD) and its Indian partner Cipla said Wednesday that India's Central Drugs Standard Control Organization has approved Afrezza inhalation powder for adults with diabetes.
MannKind expects to ship Afrezza to Cipla by the end of 2025, the companies said.
Under an exclusive marketing and distribution agreement for Afrezza, Cipla was responsible for obtaining regulatory approvals as well as marketing and sales of Afrezza in India, while MannKind supplies the product to Cipla, according to a joint statement.
Afrezza is approved in the US and Brazil, the companies added.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。